AC Immune SA Stock News

AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer's disease t

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline

ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far.

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune to Present at the SVB Securities Global Biopharma Conference

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development